Skip to main content
. 2014 Dec 10;35(3):348–358. doi: 10.1038/jcbfm.2014.218

Table 1. Description of included studies.

Study Species Model Drug Total dose Route Time of administration Unit of infarct volume Time of assessment STAIR score
Ahmad 2012 18 Wistar rats T 2 hours PEA 10 mg/kg IP 1 and 6 hours post mm3 24 hours 4
Bonfils 2006 19 Wistar rats T 0.5 hours WIN 55212-2 9 mg/kg/h IV 0.5 hours post until 22 hours mm3 7 days 2
Berger 2004 20 Wistar rats Pa SR141716 1 mg/kg IV 30 minutes post onset mm3 5 hours 3
Belayev 1995a 21 Wistar rats T 1.5 hours HU-211 4 mg/kg IV 70 minutes post onset mm3 72 hours 2
Belayev 1995b 22 Wistar rats P HU-211 4 mg/kg IV 30 minutes post onset n/a n/a 2
Garg 2010 23
 Experiments 1–4 Spr-Dawley rats T 1.5 hours PEA 10 mg/kg IP Pre, 0, 2 or 3 hours post % 24 hours  
Garg 2011 24
 Experiment 1 Spr-Dawley rats T 1.5 Lauroylethanolamide 10 mg/kg IP Pre onset % 24 hours 4
 Experiments 2 and 3     Linoleoylethanolamide 10 or 20 mg/kg          
Hayakawa 2004 36
 Experiment 1 ddY mice T 4 hours CBD 6 mg/kg IP Pre onset mm3 24 hours 3
 Experiment 2     THC 20 mg/kg          
Hayakawa 2007a 12 ddY mice T 4 hours THC 20 mg/kg IP Pre onset mm3 24 hours 3
Hayakawa 2007b 39
 Experiments 1–3 ddY mice T 4 hours THC 2, 6, 20 mg/kg IP Pre onset mm3 24 hours 3
 Experiments 4–6     CBD 0.2, 2, 6 mg/kg          
 Experiment 7     SR141716 1 mg/kg          
Hayakawa 2007c 38
 Experiments 1–3 ddY mice T 4 hours CBD 0.2, 2, 6 mg/kg IP Pre onset mm3 24 hours 5
 Experiments 4–6     THC 2, 6, 20 mg/kg   Pre onset   24 hours  
 Experiments 7 and 9     CBD 6 mg/kg   Pre-onset   24 and 72 hours  
 Experiments 8 and 15     THC 20 mg/kg   Pre onset   24 and 72 hours  
 Experiments 10–14     CBD 3 mg/kg   Pre onset, 3 hours post, at reperfusion, 1 hours or 2 hours post reperfusion   24 hours  
 Experiments 16–18     THC 10 mg/kg   Pre onset, 3 hours, reperfusion   24 hours  
 Experiment 19     SR141716 1 mg/kg   Pre onset      
                   
Hayakawa 2008 37
 Experiments 1–3 ddY mice T 4 hours CBD 0.1, 1, 3 mg/kg IP Pre onset mm3 24 hours 4
 Experiment 4     SR141716 1 mg/kg          
Hayakawa 2009 35                  
 Experiments 1–3 ddY mice T 4 hours CBD 3 mg/kg IP Days 1, 3, or 5 n/a - 4
Hu 2010 25
 Experiments 1–3 Spr-Dawley rats T 2 hours WIN 55212-2 1, 3 or 5 mg/kg IP Pre onset 1, 3, or 5 days % 72 hours 6
                   
Lavie 2001 26                  
 Experiments 1–3 Hypertensive rats P HU-211 4.5 mg/kg IV 1, 3, or 6 hours post onset % 24 hours 6
 Experiments 4–6           1, 3 or 6 hours post onset   30 days  
Leker 1999 27 Hypertensive rats P HU-211 4 mg/kg IV 1 hour post onset % 24 hours 2
Leker 2003 10
 Experiments 1–4 Sp-Dawley rats P HU-210 5, 10, 30, 45 μg/kg IV 1 hour post onset % 72 hours 5
 Experiments 5–8       45 μg/kg   1, 2, 4, or 6 hours post onset      
Mishima 2005 3
 Experiments 1–4 ddY mice T 4 hours CBD 0.2, 2, 6, or 20 mg/kg IP At pre onset mm3 24 hours 4
 Experiments 5 and 6     Abnormal CBD 6 or 20 mg/kg          
 Experiments 7 and 8     AEA 6 or 20 mg/kg          
 Experiments 9 and 10     Methanandamide 6 or 20 mg/kg          
Muthian 2004 5
 Experiments 1–3 Wistar rats T 2.5 hours WIN 55212-2 0.1, 0.3, or 1 mg/kg IV 5 minutes pre onset mm3 24 hours 5
 Experiments 4–6     SR141716 0.1, 0.3, or 1 mg/kg          
 Experiment 7     LY320153 6 mg/kg          
Murakami 2013 28                  
 Experiments 1–6 Rats P TAK-937 30, 100 mcg/kg/h IV 3, 5, or 8 hours post, until 24 hours % 48 hours 4
 Experiments 7 and 8 Aged rats Pa   100 mcg/kg/h   1 hour post until 24 hours      
 Experiment 9   Pa       1 hour post until 24 hours      
Murikinati 2010 9 C57BL/6 mice P JWH-133 1 mg/kg/day IV 4 hour pre onset mm3 3 d 2
Nagayama 1999 29
 Experiments 1–4 Spr-Dawley rats P WIN 55212-2 1 mg/kg IP 30 minutes pre-, 30, 60, or 120 minutes post- mm3 24 hours 4
 Experiment 5     SR141716 1 mg/kg          
Schomacher 2008 30
 Experiments 1 and 2 Wistar rats T 1.5 hours PEA 30 or 10 mg/kg IP 30 minutes post onset mm3 24 hours 5
 Experiment 3     AEA 10 mg/kg          
Sun 2007 40 C57BL/6 Mice T 2 hours OEA 10 mg/kg/day IP −3, −2 and −1 days pre onset mm3 48 hours 1
Sun 2013a 31
 Experiments 1 and 2 Spr-Dawley rats P WIN 55212-2 1 or 9 mg/kg IV 2 hours post onset % 24 hours 5
Sun 2013b 32
 Experiments 1–5 Spr-Dawley rats P WIN 55212-2 1, 3 or 9 mg/kg IV 2 hours % 24 hours 4
 Experiments 6 and 7     SR141716 1 or 2 mg          
Suzuki 2012a 45
 Experiments 1–4 Spr-Dawley rats T 2 hours TAK-937 3, 10, 30 or 100 μg/kg IV At reperfusion % 24 hours 4
 Experiment 5 Cynomolgus monkeys T 0.5 hour   2 μg/kg   30 minutes post reperfusion      
Suzuki 2012b 33 Spr-Dawley rats T 2 hours TAK-937 100 mcg/kg/h IV 2 hours (on reperfusion) for 24 hours mm3 24 hours 2
Teichner 2003 34
 Experiments 1 and 2 Hypertensive rats P HU-211 4.5 mg/kg IV 1 hour % 1 and 30 days 4
Zarruk 2012 41
 Experiments 1 and 3 Mice P JWH-133 0.5, 1.5 or 5 mg/kg IP 10 minutes post onset % 48 hours 6
 Experiments 4 and 5       1.5 mg/kg   10 minutes or 3 hours post onset      
Zhang 2007 43
 Experiments 1 and 3 Mice T 1 hour O-3853 1 mg/kg IV 1 hour pre- or 10 minutes post- mm3 24 hours 3
 Experiments 2 and 4     O-1966 1 mg/kg   1 hour pre- or 10 minutes post-      
Zhang 2008 11
 Experiments 1 and 2 Mice T 1 hour O-1966 1 mg/kg IV 1 hour pre onset % 24 hours 2
 Experiments 3 and 4     SR141716 5, 20 mg/kg          
 Experiments 5 and 6     SR144528 5, 20 mg/kg          
Zhang 2009 42
 Experiments 1–3 Mice T 1 hour O-1966 1, 5, or 10 mg/kg IP 1 hour pre onset % 24 hours 5
 Experiments 4–6       5 mg/kg   1 hour pre onset, 1 hour or 3 hours post reperfusion      
Zhou 2012 44
 Experiments 1–9 Kunming mice T 1.5 hours OEA 10, 20, 40 mg/kg Oral 3 days pre onset or 30, 60, 90, 150 minutes post onset mm3 24 hours 5

AEA, anandamide; CBD, cannabidiol; IP, intraperitoneal; IV, intravenous; MCAO, middle cerebral artery occlusion; OEA, oleoylethanolamide; P, permanent MCAO; PEA, palmitoylethanolamide; T, transient MCAO; THC, Δ9-tetrahydrocannabinol.

a

Photothrombotic model.